Saturday 17 October 2026 Export UFPT’s income statement to Excel — free account

UFP Technologies, Inc.

UFP Technologies, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $602.8 million, up 19.5% from fiscal 2024. In the quarter to June 2026, revenue grew 15.1%, EPS grew 20.6%, free cash flow fell 35.8% and total debt fell 19.6%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.

291.67 5.52 −1.86%

Follow UFPT

Alert me

Market cap: $2.3B
P/E: 31.2×
Fwd P/E: 23.6×
Dividend yield: —
F-score: 5/9
Altman Z: 6.86
Beneish M: −2.57
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 13.99

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	1	1	—	—	—	—	1	1	—	7	—	—

Insider Ownership 3.75%

Capital & Financial Ratios $m

Market Cap 2,300.00

Revenue 631.64

Net Income 72.30

Free Cash Flow 61.50

Net Debt 122.55

Current Ratio 3.00

Debt/Equity 0.28

P/E ratio 31.16

Fwd P/E 23.60

P/S ratio 3.57

P/B ratio 4.88

Past 5Y EPS Growth 37.66%

This Y EPS Growth 11.34%

Next Y EPS Growth 11.37%

Next Y revenue growth 9.12%

Next 5Y EPS Growth 13.43%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 81.61%

10-year low 10-year high

P/S against its own 10 years 87.91%

10-year low 10-year high

P/B against its own 10 years 84.70%

10-year low 10-year high

EV/Sales against its own 10 years 87.98%

10-year low 10-year high

EV/FCF against its own 10 years 64.28%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	5	13	20	9
Receivables	66	90	88	117
Inventory	70	88	87	100
Other	—	—	—	—
	145	195	201	235

	2023	2024	2025	Q'26
Payables	22	24	24	33
ST’ Debt	4	13	13	13
Other	—	—	—	—
	58	76	75	78

Compound Annual Growth %

	10y	5y	3y
Sales	15.81%	27.43%	19.44%
Cash Flow	22.06%	29.70%	73.02%
Earnings	24.57%	38.57%	17.80%
Book Value	15.13%	19.10%	21.29%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	154	174	—	—	—
’25	148	151	155	149	603
’24	105	110	145	144	504
’23	98	100	101	101	400
’22	71	94	97	91	354
’21	49	51	51	56	206
’20	48	43	43	45	179

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	3	16	—	—	—
’25	14	25	36	17	92
’24	11	12	20	24	67
’23	2	9	18	13	41
’22	(3)	3	0	18	18
’21	3	7	4	1	14
’20	5	6	6	8	25

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	2	14	—	—	—
’25	11	23	33	13	79
’24	9	9	14	21	54
’23	0	6	15	10	31
’22	(6)	(3)	(16)	36	11
’21	2	5	3	0	9
’20	4	5	5	7	21

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	2.24	2.68	—	—	—
’25	2.21	2.21	2.11	2.25	8.75
’24	1.64	1.75	2.11	2.10	7.58
’23	1.27	1.55	1.52	1.51	5.83
’22	0.64	1.17	2.56	1.10	5.45
’21	0.55	0.62	0.50	0.42	2.09
’20	0.52	0.31	0.40	0.55	1.77

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	20.40	22.95	26.05	27.80	30.80	44.02	56.10	103.64	152.43	178.26	Analyst estimates 2026–2028 Powerpack
	High	27.50	31.50	39.98	50.00	52.59	75.34	126.78	205.08	366.41	289.57
People
People	Employees	805	796	1,051	1,154	1,010	2,015	2,968	3,293	4,335	5,349
	Revenue/emp, $m	0.18	0.19	0.18	0.17	0.18	0.10	0.12	0.12	0.12	0.11
Income, $m
Income, $m	Revenue	146	148	190	198	179	206	354	400	504	603
	Gross margin, %	23.71	24.00	25.36	27.20	24.91	24.77	25.51	28.05	29.08	28.27
	EBT	12	12	18	24	16	21	53	54	73	83
	EBT margin, %	8.43	8.02	9.66	11.92	9.08	10.28	14.90	13.47	14.48	13.69
	Net income	8	9	14	20	13	16	42	45	59	68
	Depreciation	6	6	8	8	8	8	12	11	15	19
Per share, $
Per share, $	Revenue	20.32	20.40	25.92	26.72	23.97	27.42	46.77	52.48	65.78	78.23
	Earnings	1.11	1.27	1.95	2.66	1.79	2.11	5.52	5.89	7.69	8.87
	Cash flow	1.29	2.41	2.90	4.21	3.35	1.90	2.35	5.42	8.68	11.93
	Capex	(1.00)	(1.43)	(0.73)	(0.78)	(0.57)	(0.70)	(0.93)	(1.38)	(1.68)	(1.67)
	Free cash flow	0.29	0.98	2.17	3.43	2.78	1.20	1.41	4.05	7.01	10.26
	Book value	15.72	17.07	19.12	21.82	23.64	25.84	31.40	37.53	44.70	55.01
	Shares, m	7	7	7	7	7	8	8	8	8	8
Valuation, ×
Valuation, ×	P/E	23.20	21.87	15.48	18.65	26.03	33.30	20.94	28.16	31.80	25.03
	P/S	1.27	1.35	1.16	1.86	1.94	2.56	2.47	3.16	3.72	2.84
	P/B	1.64	1.61	1.57	2.27	1.97	2.72	3.68	4.42	5.47	4.04
	EV/Sales	1.06	1.09	1.27	1.85	1.82	2.91	2.61	3.23	4.09	3.05
	EV/FCF	73.19	22.82	15.19	14.44	15.68	66.54	86.58	41.86	38.39	23.28
Cash, $m
Cash, $m	Operating cash flow	9	17	21	31	25	14	18	41	67	92
	Capex	(7)	(10)	(5)	(6)	(4)	(5)	(7)	(10)	(13)	(13)
	Free cash flow	2	7	16	25	21	9	11	31	54	79
Balance, $m
Balance, $m	Working capital	60	65	35	36	57	49	60	86	119	126
	Total debt	1	—	25	3	1	82	55	32	202	149
	Net debt	(31)	(38)	22	(1)	(23)	71	51	27	188	129
	Shareholders’ equity	113	124	140	162	177	194	238	286	343	424
Returns, %
Returns, %	ROA	6.44	6.92	8.73	10.44	6.82	5.91	11.73	11.48	11.42	10.64
	ROIC	9.26	8.52	7.55	9.57	6.79	5.00	12.02	11.52	9.52	10.44
	ROE	7.36	7.78	10.83	13.06	7.89	8.56	19.35	17.16	18.76	17.82

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
NEOG Neogen Corporation	$2.7B	— (loss-making)	— (loss-making)	+6.51% (above 0%: growing)	n/m	+135.75% (above 0%: growing)	47.35%	(0.81%)	Compare
TMDX TransMedics Group, Inc.	$2.7B	16.0×	34.1×	+20.70% (above 0%: growing)	−59.22% (below 0%: shrinking)	−87.62% (below 0%: shrinking)	59.59%	12.50%	Compare
UFPT UFP Technologies, Inc.	$2.3B	31.2×	23.6×	+15.07% (above 0%: growing)	+20.63% (above 0%: growing)	−35.77% (below 0%: shrinking)	29.27%	16.15%
BFLY Butterfly Network, Inc.	$2.1B	— (loss-making)	— (loss-making)	+39.47% (above 0%: growing)	n/m	−113.85% (below 0%: shrinking)	71.41%	(41.90%)	Compare
AXGN AxoGen, Inc.	$2.1B	— (loss-making)	— (loss-making)	+23.06% (above 0%: growing)	n/m	−17.36% (below 0%: shrinking)	72.67%	(3.09%)	Compare
INSP Inspire Medical Systems, Inc.	$2.0B	14.8×	93.5×	−7.60% (below 0%: shrinking)	n/m	+322.84% (above 0%: growing)	85.48%	(0.26%)	Compare
ESTA Establishment Labs Holdings Inc.	$1.8B	— (loss-making)	— (loss-making)	+31.66% (above 0%: growing)	n/m	+2.75% (above 0%: growing)	70.64%	(6.35%)	Compare
ATEC Alphatec Holdings, Inc.	$1.7B	— (loss-making)	— (loss-making)	+15.07% (above 0%: growing)	n/m	−146.87% (below 0%: shrinking)	72.17%	(0.89%)	Compare
NVCR NovoCure Limited	$1.7B	— (loss-making)	— (loss-making)	+15.60% (above 0%: growing)	n/m	+105.68% (above 0%: growing)	77.61%	(5.75%)	Compare
Median of peers	$2.1B	—	—	+18.15%	—	−7.30%	71.79%	(1.99%)

All 149 Medical Devices stocks →

UFP Technologies, Inc. (UFPT) key facts

Strength: UFP Technologies, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $602.8 million, up 19.5% from fiscal 2024.
Strength: Net income was $68.3 million, or $8.87 per share (basic), a net margin of 11.3%.
UFP Technologies, Inc. (UFPT) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, UFPT traded at $291.67, a market capitalization of $2.3 billion.
At that price the stock trades at 31.2× trailing-twelve-month earnings and 3.6× sales; its P/E is higher than 82% of its own readings over the past ten years.
Return on equity was 17.8% and debt-to-equity 0.28.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 6.86 (safe zone) for fiscal 2025.